Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial.
The purpose of this study was to compare moclobemide and clomipramine in reactive depression according to the Newcastle II classification. Sixty patients were allocated to either 300 mg moclobemide, 150 mg clomipramine or placebo, all divided in 3 daily doses. Improvements occurred over time, but differences between treatments and compared with placebo were never statistically significant. Dizziness, tremor and anticholinergic symptoms were significantly more frequent with clomipramine than with moclobemide and placebo.
Larsen
J K
JK
Department of Psychiatry, Frederiksberg Hospital, Denmark.
Holm
P
P
Høyer
E
E
Mejlhede
A
A
Mikkelsen
P L
PL
Olesen
A
A
Schaumburg
E
E
D000275:Adjustment Disorders / Q000188:drug therapy* / Q000523:psychology; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D002997:Clomipramine / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D011569:Psychiatric Status Rating Scales; D011897:Random Allocation
D000928:Antidepressive Agents; D001549:Benzamides; D002997:Clomipramine; D020912:Moclobemide